Perspective Therapeutics [212Pb]VMT-α-NET cohort safety, efficacy data set for NANETS 2026 presentation
Bitget2026/10/07 10:16Perspective Therapeutics secured conference acceptance for interim safety and efficacy results from its [²¹²Pb]VMT-α-NET trial in advanced SSTR2-positive NETs. Findings will be presented Nov. 5 at the NANETS 2026 symposium in Las Vegas; earlier interim data were presented at ASCO in May 2026. Management is positioning the program as an alpha-emitting radiopharmaceutical option for patients with unresectable or metastatic disease who have not received prior RPT. Additional readouts from later cohorts remain pending, with more disclosures planned across 2026 and 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070616PRIMZONEFULLFEED9841230) on October 07, 2026, and is solely responsible for the information contained therein.
- Perspective Therapeutics secured conference acceptance for interim safety and efficacy results from its [²¹²Pb]VMT-α-NET trial in advanced SSTR2-positive NETs.
- Findings will be presented Nov. 5 at the NANETS 2026 symposium in Las Vegas; earlier interim data were presented at ASCO in May 2026.
- Management is positioning the program as an alpha-emitting radiopharmaceutical option for patients with unresectable or metastatic disease who have not received prior RPT.
- Additional readouts from later cohorts remain pending, with more disclosures planned across 2026 and 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Crypto prices
More
